Drugs / gevokizumab
Trials 19 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03798626 | May 2019 → Mar 2023 | colorectal cancer, gastroesophageal cancer, renal cell carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01211977 | Aug 2010 → Apr 2011 | Behcet disease, Muckle-Wells syndrome | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Withdrawn | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT05178576 | Jun 2022 → Feb 2026 | colon carcinoma | NSABP Foundation Inc | Withdrawn | No outcome recorded |
| Phase 2 | NCT01950312 | Aug 2013 → Oct 2015 | autoimmune inner ear disease | XOMA (US) LLC | Completed | No outcome recorded |
| Phase 2 | NCT01882491 | May 2013 → Feb 2014 | osteoarthritis | XOMA (US) LLC | Completed | No outcome recorded |
| Phase 2 | NCT01882504 | May 2013 → Oct 2015 | pyoderma gangrenosum | XOMA (US) LLC | Completed | No outcome recorded |
| Phase 2 | NCT01683396 | Jul 2012 → Feb 2014 | osteoarthritis | XOMA (US) LLC | Completed | No outcome recorded |
| Phase 2 | NCT01498874 | Dec 2011 → Apr 2013 | acne | XOMA (US) LLC | Completed | No outcome recorded |
| Phase 2 | NCT01066715 | Jan 2010 → Jul 2011 | type 2 diabetes mellitus | XOMA (US) LLC | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT02326740 | Dec 2014 → Mar 2016 | pyoderma gangrenosum | XOMA (US) LLC | Terminated | No outcome recorded |
| Phase 3 | NCT02258867 | Nov 2014 → Oct 2015 | uveitis | XOMA (US) LLC | Terminated | No outcome recorded |
| Phase 3 | NCT02315417 | Nov 2014 → Mar 2016 | pyoderma gangrenosum | XOMA (US) LLC | Terminated | No outcome recorded |
| Phase 3 | NCT02318914 | Nov 2014 → Feb 2016 | pyoderma gangrenosum | XOMA (US) LLC | Terminated | No outcome recorded |
| Phase 3 | NCT02375685 | Aug 2014 → Nov 2015 | uveitis | Servier | Terminated | No outcome recorded |
| Phase 3 | NCT02258854 | Mar 2014 → Oct 2017 | uveitis | XOMA (US) LLC | Terminated | No outcome recorded |
| Phase 3 | NCT01965145 | Nov 2012 → Jul 2015 | Behcet disease | Servier | Terminated | No outcome recorded |
| Phase 3 | NCT01747538 | Oct 2012 → Jun 2016 | uveitis | XOMA (US) LLC | Terminated | No outcome recorded |
| Phase 3 | NCT01684345 | Aug 2012 → Feb 2016 | uveitis | XOMA (US) LLC | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02293564 | Mar 2013 → Jan 2015 | osteoarthritis | XOMA (US) LLC | Completed | No outcome recorded |
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00541983 Comparator | Sep 2007 → Jul 2009 | type 2 diabetes mellitus | XOMA (US) LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00513214 Comparator | Jul 2007 → Jun 2009 | type 2 diabetes mellitus | XOMA (US) LLC | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT01144975 Comparator | May 2010 → Oct 2011 | type 2 diabetes mellitus | XOMA (US) LLC | Completed | No outcome recorded |
| Phase 2 | NCT00998699 Comparator | Feb 2010 → Aug 2013 | type 1 diabetes mellitus | XOMA (US) LLC | Completed | No outcome recorded |
| Phase 2 | NCT01788033 Comparator | Sep 2009 → Sep 2013 | type 1 diabetes mellitus | University of Zurich | Completed | No outcome recorded |
| Phase 2 | NCT00777816 Comparator | Feb 2009 → Oct 2014 | rheumatoid arthritis | XOMA (US) LLC | Suspended | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 27 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gevokizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01747538 ↗ |
| Known as | VPM-087 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743026 ↗ |
| Known as | XOMA 052 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01066715 ↗ |
| Action | Inhibit | “This novel IL-1β-neutralizing antibody improved glycemia, possibly via restored insulin production and action, and reduced inflammation in patients with type 2 diabetes.” PMID 22699287 ↗ Jun 20121“Interleukin-1 beta negative allosteric modulator” CHEMBL1743026 ↗ |
| Modality | Monoclonal antibody | “Gevokizumab is a novel, human-engineered monoclonal anti-IL-1β antibody.” PMID 22699287 ↗ Jun 2012 |
| Route | Intravenous | “Single IV infusion” NCT00513214 ↗ |
| Target | IL1B | “Interleukin-1 beta negative allosteric modulator” CHEMBL1743026 ↗ |